Maria Rell‐Bakalarska

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Peter Nash, Bruce Kirkham, Masato Okada et al. · The Lancet · 2017 · 405 citations · Full text

Medicine, Immunology, Pharmacotherapy +13

Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study

Mark C. Genovese, Roy Fleischmann, Alan Kivitz et al. · Arthritis & Rheumatology · 2015 · 270 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +12

High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti–tumor necrosis factor α treatment

Maria Ziółkowska, Anna Radzikowska, Grazyna Luszczykiewicz et al. · Arthritis & Rheumatism · 2002 · 200 citations

Life Sciences, Immunology, Orthopedic Surgery +17

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Atul Deodhar, Alice B. Gottlieb, Wolf‐­Henning Boehncke et al. · The Lancet · 2018 · 184 citations

Medicine, Clinical Sciences, Pharmacotherapy +7

MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16

Mikkel Østergaard, L. Jacobsson, C. Schaufelberger et al. · Annals of the Rheumatic Diseases · 2014 · 35 citations · Full text

Medicine, Pharmacotherapy, Radiology +17